Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET.A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section. A replay of the webcast will be available for approximately 90 days.About Kiora PharmaceuticalsKi ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Dr. Brady's conversation with Andreas Argyrides, Managing Director, Senior Biotech. ...

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Accessibility Statement] Skip NavigationWALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36 ...

– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annu ...

Core Insights - TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel therapeutics to address resistance to cancer immunotherapy [1] - The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 pm ET [1] Company Overview - TuHURA is developing technologies to overcome primary and acquired resistance to cancer immunotherapy, which are common reasons for the failure of these treatments [1] - The lead product, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors and is currently in a Phase 3 registration trial as an adjunctive therapy to Keytruda® for advanced or metastatic Merkel Cell Carcinoma [1] Recent Developments - TuHURA acquired TBS-2025 through its merger with Kineta Inc. on June 30, 2025; TBS-2025 is a VISTA inhibiting monoclonal antibody moving into Phase 2 development for mutNPM1 r/r AML [1] - The company is also leveraging Delta Opioid Receptor technology to develop first-in-class bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells [1]

Group 1 - Oppenheimer Holdings (OPY) reported a strong quarter, benefiting from relatively fixed costs and operating leverage across its segments [2] - Wealth management performed well due to higher Assets Under Management (AUM) and increased market valuations [2] - The Valkyrie Trading Society is a team of analysts focused on high conviction, obscure developed market ideas that are expected to yield non-correlated and outsized returns in the current economic environment [2] Group 2 - The Value Lab is an investment group that targets long-only value ideas, aiming for a portfolio yield of approximately 4% [1] - The Value Lab provides members with real-time updates, 24/7 chat support, regular global market news reports, feedback on stock ideas, monthly new trades, quarterly earnings write-ups, and daily macro opinions [2]

Financial Performance - Oppenheimer Holdings Inc. reported a net income of $74.4 million for Q4 2025, a 593.1% increase from $10.7 million in Q4 2024, with revenue rising 25.9% to $472.6 million[1][2]. - For the full year 2025, net income reached $148.4 million, up 107.4% from $71.6 million in 2024, while revenue increased 14.4% to $1.6 billion[2]. - Total revenue for FY-25 was $591.3 million, a 32.0% increase from $447.6 million in FY-24[30]. - Pre-tax income for FY-25 was $56.2 million, compared to a loss of $39.6 million in FY-24[30]. - The effective tax rate improved to 29.9% in FY-25 from 32.6% in FY-24[37]. Segment Performance - Wealth Management segment revenue for Q4 2025 was $287.3 million, a 13.3% increase year-over-year, with pre-tax income rising 84.0% to $98.8 million[12][21]. - Capital Markets segment revenue for Q4 2025 was $182.9 million, a 53.3% increase compared to Q4 2024, with pre-tax income of $52.8 million compared to a loss of $5.0 million a year ago[16][19]. - The Capital Markets segment saw a significant increase in investment banking activity, with advisory fees from investment banking up 41.3% year-over-year[19]. - Investment banking revenue increased by 56.0% to $260.4 million from $166.8 million in the prior year[30]. - Equities underwriting fees surged by 163.8% compared to the prior year, reflecting higher new issuance activity in key sectors[32]. - Fixed income underwriting fees increased by $7.1 million, or 60.0%, due to a higher number of public finance transactions[32]. Expenses and Dividends - Compensation expenses increased to $260.1 million in Q4 2025, up from $256.4 million in Q4 2024, primarily due to higher production-related expenses[3][7]. - Non-compensation expenses for the full year 2025 rose to $410.4 million, reflecting higher underwriting and technology-related costs[3][7]. - Total expenses for FY-25 were $535.1 million, up 9.8% from $487.2 million in FY-24[30]. - The company declared a special dividend of $1.00 per share, payable in January 2026, and repurchased 46,292 shares at an average price of $64.36 during the year[7][9]. - The company announced a quarterly dividend of $0.18 per share for Q4 2025, payable on February 27, 2026[37]. Market Position and Outlook - Assets Under Management (AUM) reached a record $55.2 billion as of December 31, 2025, reflecting a $5.8 billion increase from the previous year due to market appreciation[15][21]. - The company remains well-positioned to navigate evolving market conditions and capitalize on opportunities across its businesses as it enters 2026[9]. - Retail commissions increased by 6.2% year-over-year, reaching a record high due to higher retail transaction volumes[26]. - Advisory fees rose by 14.9% from the prior year, driven by higher billable AUM and increased incentive fees from alternative investments[26].

Core Insights - Oppenheimer Holdings Inc. reported significant growth in net income and revenue for both the fourth quarter and the full year of 2025, with net income increasing by 593.1% year-over-year in Q4 and 107.4% for the full year [1][2][3] Financial Performance - For Q4 2025, net income was $74.4 million, or $7.08 per share, compared to $10.7 million, or $1.04 per share, in Q4 2024, marking a 593.1% increase [1] - Revenue for Q4 2025 reached $472.6 million, up 25.9% from $375.4 million in Q4 2024 [1] - For the full year 2025, net income was $148.4 million, or $14.13 per share, compared to $71.6 million, or $6.91 per share, in 2024, reflecting a 107.4% increase [2] - Total revenue for 2025 was $1.6 billion, a 14.4% increase from $1.4 billion in 2024 [2] Business Segments - The Wealth Management segment reported Q4 2025 revenue of $287.3 million, a 13.3% increase year-over-year, with pre-tax income rising 84.0% to $98.8 million [9] - The Capital Markets segment generated revenue of $182.9 million in Q4 2025, a 53.3% increase compared to the previous year, with pre-tax income of $52.8 million compared to a loss of $5.0 million in Q4 2024 [13] - For the full year 2025, Wealth Management revenue was $1.035 billion, up 6.5% from the prior year, while Capital Markets revenue was $591.3 million, a 32.1% increase [17][22] Market Conditions - The company's performance was bolstered by favorable macroeconomic conditions, including a sustained rise in equity markets and strong corporate earnings, which helped offset concerns about trade tensions and a softening labor market [3][4] - Interest in artificial intelligence platforms contributed to the strength of equity markets, further supporting the company's revenue growth [3] Shareholder Returns - The company declared a special dividend of $1.00 per share in January 2026, totaling $10.5 million, and repurchased 46,292 shares at an average price of $64.36 during the year [5][26][28] Operating Metrics - The company's assets under management (AUM) reached a record $55.2 billion by December 31, 2025, up $5.8 billion from the previous year, primarily due to market appreciation [15][24] - Compensation expenses increased by 6.2% year-over-year, while non-compensation expenses rose by 1.8% due to higher underwriting and technology-related costs [19][20]

Group 1 - M-tron Industries, Inc. will host virtual 1x1 meetings with investors at the Oppenheimer 11 Annual Emerging Growth Conference on February 3, 2026 [1] - The company expresses appreciation for Oppenheimer & Co. Inc.'s support and the opportunity to engage with investors [1] Group 2 - M-tron Industries, Inc. designs, manufactures, and markets high-reliability frequency and spectrum control products and solutions [2] - The company provides comprehensive support throughout the product life cycle, including design, prototyping, production, and upgrades [2] - M-tron has facilities in Orlando, Florida, Yankton, South Dakota, a sales office in Hong Kong, and a manufacturing facility in Noida, India [2]

Group 1 - Oppenheimer upgraded Relay Therapeutics Inc. (RLAY) to Outperform from Perform, resulting in a significant increase in stock price since the upgrade on the 26th [1] - The stock price of Relay Therapeutics has seen a considerable boost following the upgrade, indicating positive market sentiment [1] Group 2 - The focus of the analysis is on identifying promising biotechnology companies that are innovating through unique mechanisms of action, first-in-class therapies, or platform technologies [1] - The approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]